Hengrui Pharma(SH:600276) Huan Qiu Wang·2025-11-21 14:52Core Viewpoint - The 27th Academic Conference of the Diabetes Society of the Chinese Medical Association was successfully held in Xi'an, where the results of the phase III clinical trial (GEMINI-1 study) for HRS9531, China's first independently developed GLP-1/GIP dual receptor agonist injection for overweight or obese adults, were announced [1] Group 1: Company Developments - Heng Rui Medicine's Vice President, Huo Shiwen, provided insights into the company's product layout in the weight loss sector and the development progress of HRS9531 [1] - Heng Rui Medicine has submitted a new drug application for HRS9531 for long-term weight management in China, which has been accepted, indicating potential benefits for a large number of overweight patients in the near future [1] - A series of clinical studies related to HRS9531 are currently underway, targeting various weight-related diseases such as obstructive sleep apnea, heart failure, osteoarthritis, and polycystic ovary syndrome, which may offer treatment options for a broader patient population and enhance overall clinical benefits [1] Group 2: Clinical Trial Insights - Professor Zhao Lin from the Endocrinology Department of Zhongshan Hospital, Fudan University, provided a detailed presentation on the phase III clinical results of HRS9531 injection during the conference [1]